BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 7627966)

  • 1. Farnesyltransferase inhibitors block the neurofibromatosis type I (NF1) malignant phenotype.
    Yan N; Ricca C; Fletcher J; Glover T; Seizinger BR; Manne V
    Cancer Res; 1995 Aug; 55(16):3569-75. PubMed ID: 7627966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells.
    Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R
    Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Farnesyltransferase inhibitors are inhibitors of Ras but not R-Ras2/TC21, transformation.
    Carboni JM; Yan N; Cox AD; Bustelo X; Graham SM; Lynch MJ; Weinmann R; Seizinger BR; Der CJ; Barbacid M
    Oncogene; 1995 May; 10(10):1905-13. PubMed ID: 7761092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of neurofibromatosis type I gene product as an insoluble GTPase-activating protein toward ras p21.
    Hattori S; Maekawa M; Nakamura S
    Oncogene; 1992 Mar; 7(3):481-5. PubMed ID: 1549362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ras-interacting domain of Ral GDP dissociation stimulator like (RGL) reverses v-Ras-induced transformation and Raf-1 activation in NIH3T3 cells.
    Okazaki M; Kishida S; Murai H; Hinoi T; Kikuchi A
    Cancer Res; 1996 May; 56(10):2387-92. PubMed ID: 8625316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant regulation of ras proteins in malignant tumour cells from type 1 neurofibromatosis patients.
    Basu TN; Gutmann DH; Fletcher JA; Glover TW; Collins FS; Downward J
    Nature; 1992 Apr; 356(6371):713-5. PubMed ID: 1570015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Farnesyltransferase inhibitor (L-744,832) restores TGF-beta type II receptor expression and enhances radiation sensitivity in K-ras mutant pancreatic cancer cell line MIA PaCa-2.
    Alcock RA; Dey S; Chendil D; Inayat MS; Mohiuddin M; Hartman G; Chatfield LK; Gallicchio VS; Ahmed MM
    Oncogene; 2002 Nov; 21(51):7883-90. PubMed ID: 12420225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection against malignant conversion in SENCAR mouse skin by all trans retinoic acid: inhibition of the ras p21-processing enzyme farnesyltransferase and Ha-ras p21 membrane localization.
    Agarwal R; Mohan RR; Ahmad N; Mukhtar H
    Mol Carcinog; 1996 Sep; 17(1):13-22. PubMed ID: 8876671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farnesyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines.
    Lerner EC; Zhang TT; Knowles DB; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1997 Sep; 15(11):1283-8. PubMed ID: 9315095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
    Kelloff GJ; Lubet RA; Fay JR; Steele VE; Boone CW; Crowell JA; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 1997 Apr; 6(4):267-82. PubMed ID: 9107432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Schwann cells from neurofibromin deficient mice exhibit activation of p21ras, inhibition of cell proliferation and morphological changes.
    Kim HA; Rosenbaum T; Marchionni MA; Ratner N; DeClue JE
    Oncogene; 1995 Jul; 11(2):325-35. PubMed ID: 7624147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of Ras effector mutant interactions with the NF1-GAP related domain.
    Marshall MS; Hettich LA
    Oncogene; 1993 Feb; 8(2):425-31. PubMed ID: 8426748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Farnesylation of p21 Ras proteins in Xenopus oocytes.
    Zhao J; Kung HF; Manne V
    Cell Mol Biol Res; 1994; 40(4):313-21. PubMed ID: 7866432
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MEK and ERK activation in ras-disabled RBL-2H3 mast cells and novel roles for geranylgeranylated and farnesylated proteins in Fc epsilonRI-mediated signaling.
    Graham TE; Pfeiffer JR; Lee RJ; Kusewitt DF; Martinez AM; Foutz T; Wilson BS; Oliver JM
    J Immunol; 1998 Dec; 161(12):6733-44. PubMed ID: 9862703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
    Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
    Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Oncogene; 1998 Mar; 16(11):1467-73. PubMed ID: 9525745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibitors of farnesyltransferase and Ras processing peptidase.
    Hall CC; Watkins JD; Ferguson SB; Foley LH; Georgopapadakou NH
    Biochem Biophys Res Commun; 1995 Dec; 217(3):728-32. PubMed ID: 8554591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.